ANI Pharmaceuticals, Inc. delivered robust 2025 results and issued bullish 2026 guidance. Learn more about ANIP stock here.
Zacks Investment Research on MSN
Strength seen in ANI (ANIP): Can its 10.6% jump turn into more strength?
ANI Pharmaceuticals ANIP shares rallied 10.6% in the last trading session to close at $84.35. This move can be attributable ...
Amid the dozens of publicly traded firms in Minnesota, Baudette-based ANI Pharmaceuticals Inc. often flies under the radar. The pharmaceutical company about five hours north of Minneapolis has grown ...
BAUDETTE, Minn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and ...
ANI is expanding its portfolio of branded drugs. The company has acquired the new drug applications from Sandoz for Oxistat lotion, Veregen ointment, and Pandel cream and the abbreviated new drug ...
ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...
ANI is offering prucalopride tablets, which is the generic of Takeda's Motegrity. Motegrity is used in adults to treat chronic idiopathic constipation. "We are delighted to build momentum early in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback